New drug candidates for lysosomal storage disorders, parkinsonism and type 2 diabetes

Researchers at the Leiden Institute of Chemistry and the Academic Medical Center Amsterdam have developed new, proprietary leads for drug development towards glycosphingolipidoses including Gaucher
disease, towards Parkinsonism and towards type 2 diabetes. The discovery is based on the long-standing
expertise in the study of glycosphingolipid metabolism in health and disease. Building on previously
developed lipophilic iminosugars the team has discovered two different sets of compounds.


Click here for more information on this licensing opportunity